Inozyme Accounts Payable vs Cash And Short Term Investments Analysis

INZY Stock  USD 5.54  0.39  7.57%   
Inozyme Pharma financial indicator trend analysis is infinitely more than just investigating Inozyme Pharma recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Inozyme Pharma is a good investment. Please check the relationship between Inozyme Pharma Accounts Payable and its Cash And Short Term Investments accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inozyme Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
For more information on how to buy Inozyme Stock please use our How to Invest in Inozyme Pharma guide.

Accounts Payable vs Cash And Short Term Investments

Accounts Payable vs Cash And Short Term Investments Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Inozyme Pharma Accounts Payable account and Cash And Short Term Investments. At this time, the significance of the direction appears to have strong relationship.
The correlation between Inozyme Pharma's Accounts Payable and Cash And Short Term Investments is 0.73. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Cash And Short Term Investments in the same time period over historical financial statements of Inozyme Pharma, assuming nothing else is changed. The correlation between historical values of Inozyme Pharma's Accounts Payable and Cash And Short Term Investments is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Inozyme Pharma are associated (or correlated) with its Cash And Short Term Investments. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash And Short Term Investments has no effect on the direction of Accounts Payable i.e., Inozyme Pharma's Accounts Payable and Cash And Short Term Investments go up and down completely randomly.

Correlation Coefficient

0.73
Relationship DirectionPositive 
Relationship StrengthSignificant

Accounts Payable

An accounting item on the balance sheet that represents Inozyme Pharma obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Inozyme Pharma are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of Inozyme Pharma balance sheet. This account contains Inozyme Pharma investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Inozyme Pharma fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.
Most indicators from Inozyme Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Inozyme Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inozyme Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
For more information on how to buy Inozyme Stock please use our How to Invest in Inozyme Pharma guide.Selling General Administrative is likely to drop to about 14.5 M in 2024. Issuance Of Capital Stock is likely to drop to about 63.3 M in 2024
 2021 2022 2023 2024 (projected)
Interest Income211K1.9M4.1M4.3M
Net Interest Income211K1.9M4.1M4.3M

Inozyme Pharma fundamental ratios Correlations

0.970.950.980.970.85-0.05-0.880.740.420.80.850.781.00.780.891.0-0.730.940.90.83-0.630.870.991.01.0
0.970.960.930.920.880.16-0.930.640.190.680.810.620.960.790.930.98-0.670.940.920.85-0.560.890.960.980.97
0.950.960.950.940.940.12-0.930.750.20.730.90.630.940.710.910.95-0.780.960.880.87-0.680.880.950.950.94
0.980.930.951.00.91-0.16-0.830.850.480.880.930.830.970.670.810.97-0.860.930.840.77-0.790.820.990.960.96
0.970.920.941.00.91-0.18-0.810.860.490.890.930.830.970.630.80.97-0.870.910.820.75-0.790.820.990.960.95
0.850.880.940.910.910.03-0.810.860.20.770.960.640.840.530.720.86-0.90.890.780.73-0.830.810.880.840.83
-0.050.160.12-0.16-0.180.03-0.38-0.42-0.88-0.54-0.19-0.61-0.060.320.32-0.030.290.170.280.410.350.02-0.080.0-0.01
-0.88-0.93-0.93-0.83-0.81-0.81-0.38-0.57-0.03-0.55-0.74-0.48-0.88-0.89-0.93-0.890.6-0.97-0.97-0.980.49-0.8-0.86-0.9-0.89
0.740.640.750.850.860.86-0.42-0.570.60.950.960.860.730.350.440.73-0.960.740.580.5-0.950.640.780.70.69
0.420.190.20.480.490.2-0.88-0.030.60.770.420.870.430.150.050.39-0.460.230.160.0-0.490.260.420.370.39
0.80.680.730.880.890.77-0.54-0.550.950.770.890.970.80.450.470.79-0.880.730.610.48-0.860.680.830.770.77
0.850.810.90.930.930.96-0.19-0.740.960.420.890.780.840.480.650.85-0.950.860.720.67-0.90.770.880.830.81
0.780.620.630.830.830.64-0.61-0.480.860.870.970.780.780.490.440.76-0.760.660.580.42-0.740.630.790.740.75
1.00.960.940.970.970.84-0.06-0.880.730.430.80.840.780.790.891.0-0.720.940.90.82-0.620.870.991.01.0
0.780.790.710.670.630.530.32-0.890.350.150.450.480.490.790.810.78-0.330.840.940.87-0.230.690.720.80.81
0.890.930.910.810.80.720.32-0.930.440.050.470.650.440.890.810.9-0.490.890.880.91-0.360.780.870.920.91
1.00.980.950.970.970.86-0.03-0.890.730.390.790.850.761.00.780.9-0.730.940.90.82-0.630.890.991.01.0
-0.73-0.67-0.78-0.86-0.87-0.90.290.6-0.96-0.46-0.88-0.95-0.76-0.72-0.33-0.49-0.73-0.76-0.6-0.570.99-0.56-0.8-0.7-0.69
0.940.940.960.930.910.890.17-0.970.740.230.730.860.660.940.840.890.94-0.760.970.94-0.670.820.940.940.94
0.90.920.880.840.820.780.28-0.970.580.160.610.720.580.90.940.880.9-0.60.970.95-0.510.770.880.910.91
0.830.850.870.770.750.730.41-0.980.50.00.480.670.420.820.870.910.82-0.570.940.95-0.470.660.810.840.84
-0.63-0.56-0.68-0.79-0.79-0.830.350.49-0.95-0.49-0.86-0.9-0.74-0.62-0.23-0.36-0.630.99-0.67-0.51-0.47-0.44-0.71-0.6-0.59
0.870.890.880.820.820.810.02-0.80.640.260.680.770.630.870.690.780.89-0.560.820.770.66-0.440.840.870.87
0.990.960.950.990.990.88-0.08-0.860.780.420.830.880.790.990.720.870.99-0.80.940.880.81-0.710.840.990.99
1.00.980.950.960.960.840.0-0.90.70.370.770.830.741.00.80.921.0-0.70.940.910.84-0.60.870.991.0
1.00.970.940.960.950.83-0.01-0.890.690.390.770.810.751.00.810.911.0-0.690.940.910.84-0.590.870.991.0
Click cells to compare fundamentals

Inozyme Pharma Account Relationship Matchups

Inozyme Pharma fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets47.9M169.4M123.5M139.2M200.8M132.8M
Other Current Liab2.3M6.9M8.5M7.5M12.6M7.2M
Total Current Liabilities3.2M10.0M11.6M14.7M14.7M10.4M
Total Stockholder Equity(33.2M)158.1M109.3M118.6M140.5M87.9M
Net Tangible Assets(33.2M)158.1M109.3M118.4M136.2M74.5M
Property Plant And Equipment Net298K2.6M4.4M3.6M2.6M2.5M
Net Debt(31.6M)(158.6M)(19.9M)(26.1M)12.0M12.6M
Retained Earnings(34.7M)(91.1M)(147.7M)(214.8M)(285.9M)(271.6M)
Accounts Payable901K3.1M2.4M2.5M1.2M2.0M
Cash31.6M159.9M23.3M32.9M34.6M42.4M
Non Current Assets Total484K18.4M8.2M7.8M4.6M7.3M
Non Currrent Assets Other56K3.5M3.4M3.8M1.7M2.3M
Cash And Short Term Investments47.1M159.9M111.8M127.9M188.6M124.4M
Net Receivables104K155K62K115K385K404.3K
Common Stock Shares Outstanding15.2M23.4M23.6M37.8M51.8M30.6M
Short Term Investments15.5M119.7M88.5M95.0M154.0M88.0M
Liabilities And Stockholders Equity47.9M169.4M123.5M139.4M200.8M132.8M
Non Current Liabilities Total77.9M1.3M2.6M6.1M45.7M25.2M
Capital Surpluse1.4M249.2M256.9M333.4M383.4M402.5M
Other Current Assets224K3.3M3.5M3.5M7.3M7.6M
Other Stockholder Equity(76.5M)79.8M133.4M333.6M426.4M447.7M
Total Liab81.2M11.3M14.3M20.8M60.4M32.7M
Net Invested Capital(33.2M)158.1M109.3M122.5M185.2M96.8M
Total Current Assets47.5M151.0M115.3M131.4M196.3M125.5M
Accumulated Other Comprehensive Income5K2K18K(205K)41K43.1K
Net Working Capital44.2M141.0M103.7M116.7M181.6M115.1M
Property Plant Equipment298K2.6M4.4M2.0M2.3M2.1M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Inozyme Stock Analysis

When running Inozyme Pharma's price analysis, check to measure Inozyme Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inozyme Pharma is operating at the current time. Most of Inozyme Pharma's value examination focuses on studying past and present price action to predict the probability of Inozyme Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inozyme Pharma's price. Additionally, you may evaluate how the addition of Inozyme Pharma to your portfolios can decrease your overall portfolio volatility.